Items Tagged ‘General Sarcoma’

February 4th, 2015

YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma

By

The U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YONDELIS® (trabectedin) to treat patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes. YONDELIS® is a novel, multimodal, synthetically produced antitumor agent, originally derived from the sea squirt, Ecteinascidia turbinata. The anti-cancer medicine works […]

View full entry

Tags: General Sarcoma, News, Sarcoma, Soft Tissue Sarcomas, soft tissue sardcoma, trabectedin, yondelis


September 6th, 2013

Carbon Ion Beam Radiation Effective in Spinal Sarcomas

By

Radiation therapy with carbon ions is a safe and effective treatment for people with inoperable spinal sarcomas, according to the results of a study published in Cancer. Sarcomas are a varied group of cancers arising from fibrous tissue, adipose tissue (fat cells), skeletal muscle, smooth muscle, blood vessels, lymph vessels, nervous tissue, mesenchymal cells, bone, […]

View full entry

Tags: General Sarcoma, News, Sarcoma


June 13th, 2012

Regorafenib May Expand GIST Treatment Options

By

Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical trial—were presented at the 2012 Annual Meeting of the American Society of Clinical Oncology. GIST is a type of soft tissue sarcoma that develops in the stomach, small […]

View full entry

Tags: General Sarcoma, News, Sarcoma, Soft Tissue Sarcomas


May 7th, 2012

Votrient Approved for the Treatment of Sarcoma

By

The U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. It is the first new drug in decades to treat this type of cancer. Soft tissue sarcomas are cancers that affect the connective and supportive tissues, which include bones, […]

View full entry

Tags: General Sarcoma, News, Sarcoma


April 9th, 2012

Longer Treatment with Gleevec Effective Against Gastrointestinal Stromal Tumors (GIST)

By

In a Phase III clinical trial, three years of adjuvant (post-surgery) treatment with Gleevec® (imatinib) resulted in better survival than one year of adjuvant treatment among patients with high-risk gastrointestinal stromal tumors (GIST). These results were published in the Journal of the American Medical Association. GIST is a type of soft tissue sarcoma that develops […]

View full entry

Tags: General Sarcoma, News, Sarcoma


April 4th, 2012

Genetic Change Linked with Rhabdomyosarcoma Survival

By

For children with rhabdomyosarcoma, a test for a specific genetic change could eventually improve risk estimates and treatment decisions. These results were published in the Journal of Clinical Oncology. Rhabdomyosarcoma is a soft-tissue cancer that arises from skeletal muscle. It is the most common soft-tissue sarcoma among children. Treatment for rhabdomyosarcoma often involves chemotherapy and […]

View full entry

Tags: General Sarcoma, News, Sarcoma


February 29th, 2012

FDA Updates Use of Gleevec for Gastrointestinal Stromal Tumors

By

In changes approved by the US Food and Drug Administration (FDA), the prescribing information for Gleevec® (imatinib) now notes that three years of adjuvant (post-surgery) treatment results in better survival than one year of adjuvant treatment among patients with high-risk gastrointestinal stromal tumors (GIST).[1] GIST is a type of soft tissue sarcoma that develops in […]

View full entry

Tags: General Sarcoma, News, Sarcoma


September 26th, 2011

Halaven Promising in Soft-Tissue Sarcoma

By

The chemotherapy drug Halaven™ (eribulin mesylate) may be a promising therapy for certain types of soft-tissue sarcoma. These findings were recently reported in the Lancet Oncology. Halaven—which was derived from a marine sponge—is a chemotherapy drug that affects cell division. It was approved by the US Food and Drug Administration in November, 2010, for the treatment […]

View full entry

Tags: General Sarcoma, News, Sarcoma


July 15th, 2011

Stay on Top of Your Family History of Cancer

By

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically with your healthcare provider. This was the conclusion of a study published in […]

View full entry

Tags: All Cancer Types, Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumors, General Bone Cancer


January 8th, 2008

Sutent® Linked with Heart Problems

By

Sutent® Linked with Heart Problems According to the results of a study published in the Lancet, treatment with Sutent® (sunitinib) was linked with the development of heart problems in some patients with metastatic gastrointestinal stromal tumors. Sutent is an oral targeted agent that works by inhibiting multiple biologic pathways involved in the growth, replication, and […]

View full entry

Tags: General Sarcoma, News